Please find enclosed herewith extract of statement of Unaudited Consolidated Financial Results for the quarter and six months 30th September, 2024 published in newspapers, Business Standard -All ...

NILACHAL REFRACTORIES LTD. - Board Meeting Intimation for Board Meeting Is Scheduled To Declared 2Nd Quarter For Financial 2024-25.

Reflecting RHI Magnesita’s mission to master heat for enabling modern industries to build a sustainable world, 4PRO goes beyond traditional refractory offerings. With this new approach, the company ...

HarbisonWalker International is investing $13.9 million in Fulton, creating 11 new jobs with a modern facility expanding ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

RHI Magnesita expects 2024 adjusted Ebita between EUR400 million and EUR410 million, similar to EUR409 million it had reported for 2023. Looking further ahead, the company said it remained well ...

Checkpoint Inhibitor Refractory Cancer Market Uncover key developments in the checkpoint inhibitor refractory cancer market, focusing on ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...

The therapy was cleared to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) after showing complete remission in 63% of efficacy evaluable patients during Autolus’ ...